MYOM2 and monoclonal gammopathy: This indicates that either the residual M protein is arising from a residual non-malignant monoclonal gammopathy of undetermined significance or that it represents a malignant clone that is not capable of proliferation due a microenvironment made inhospitable following therapy.26 In either event, this finding should raise some caution to the pursuit of minimal residual disease-negative state, as a proportion of patients may have excellent outcome even without achieving CR.